Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for the treatment of advanced and metastatic cancers, has been awarded grant funding as part of Round 3 of the New Jersey Commission on Science, Innovation, and Technology Direct Financial Assistance component (Phase I&II) of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer Program (STTR).
This award will enable early-stage preclinical validation of therapeutic leads previously supported by the SBIR and STTR Phase I grants. Novel therapeutic platforms developed by Manhattan BioSolutions leverage pathogen-specific immune responses to fight disease, particularly cancers. Dr. Borys Shor, CEO of Manhattan BioSolutions, commented: “This award expands our capacity to discover novel therapies at the intersection of innate immunity, age-related diseases, and cancer. We expect to have a deep pipeline of discovery stage products by year-end and bring those into human trials in 2023.”
About Manhattan BioSolutions
Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the development of immunotherapies that target microbial recognition and inflammatory signaling pathways for the treatment of advanced cancers and immune-mediated diseases. Manhattan BioSolutions leverages two innovative therapeutic modalities for drug discovery: biologic therapies that selectively destroy cancer cells while sparing healthy tissues and synthetic microbes — genetically engineered living drugs. The company has established partnerships with Stony Brook University, The University at Buffalo, INSERM, EVQLV and has been awarded grants by the National Institutes of Health (NIH) and the National Science Foundation (NSF).
Contact for investor inquiries
Jordana Lovett, PhD
Director of Investor Relations